Advertisement

Kidney Cancer Medications

Here's a list of the approved drugs to treat kidney cancer. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Bavencio
GENERIC NAME avelumab
DRUG INDICATION

Bavencio is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer—both as maintenance therapy and for patients who progress on chemotherapy—metastatic Merkel cell carcinoma and advanced kidney cancer (renal cell carcinoma).

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG INDICATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

DRUG Opdivo
GENERIC NAME nivolumab
DRUG INDICATION

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, metastatic small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, recurrent or metastatic esophageal cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

DRUG Yervoy
GENERIC NAME ipilimumab
DRUG INDICATION

Yervoy is a checkpoint inhibitor approved for advanced or metastatic melanoma, and in combination with Opdivo for kidney cancer (renal cell carcinoma), colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations (MSI-high/dMMR), advanced liver cancer and metastatic or recurrent non-small-cell lung cancer.

DRUG Afinitor
GENERIC NAME everolimus
DRUG INDICATION

Afinitor is a kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in previously treated postmenopausal women, as well as for advanced kidney cancer and advanced or metastatic neuroendocrine tumors of the lung, pancreas, and gastrointestinal tract.

DRUG Avastin
GENERIC NAME bevacizumab
DRUG INDICATION

Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer, liver cancer, and ovarian, fallopian tube or primary peritoneal cancer. Mvasi and Zirabev are biosimilar medications.

DRUG Cabometyx
GENERIC NAME cabozantinib
DRUG INDICATION

Cabometyx is a multikinase inhibitor approved for advanced kidney cancer (renal cell carcinoma) and previously treated liver cancer (hepatocellular carcinoma).

DRUG Inlyta
GENERIC NAME axitinib
DRUG INDICATION

Inlyta is a kinase inhibitor approved for previously treated advanced kidney cancer (renal cell carcinoma).

DRUG Lenvima
GENERIC NAME lenvatinib
DRUG INDICATION

Lenvima is a multikinase inhibitor approved for treatment of recurrent or metastatic thyroid cancer, previously treated kidney cancer and inoperable liver cancer.

DRUG Nexavar
GENERIC NAME sorafenib
DRUG INDICATION

Nexavar is a multikinase inhibitor approved for treatment of inoperable liver cancer that can't be surgically removed, advanced kidney cancer and recurrent or metastatic thyroid cancer.

DRUG Rozlytrek
GENERIC NAME entrectinib
DRUG INDICATION

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

DRUG Sutent
GENERIC NAME sunitib
DRUG INDICATION

Sutent is a kinase inhibitor approved for treatment of gastrointestinal stromal tumor, pancreatic neuroendocrine tumors and advanced kidney cancer (renal cell carcinoma), and for adjuvant treatment of high-risk kidney cancer after surgery.

DRUG Torisel
GENERIC NAME temsirolimus
DRUG INDICATION

Torisel is a kinase inhibitor approved for the treatment of advanced kidney cancer (renal cell carcinoma).

DRUG Vitrakvi
GENERIC NAME larotrectinib
DRUG INDICATION

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

DRUG Votrient
GENERIC NAME pazopanib
DRUG INDICATION

Votrient is a multikinase inhibitor approved for the treatment of advanced kidney cancer (renal cell carcinoma) and previously treated soft tissue sarcoma.


Advertisement